Wedbush Securities’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Wedbush Securities’s Portfolio AST Stock Details AST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-11,000	Closed	-$25K	–	930
2017 Q4	$25K	Buy	+11,000	New	+$27.8K	﹤0.01%	840
2017 Q2	–	Sell	-18,698	Closed	-$64K	–	908
2017 Q1	$64K	Buy	+18,698	New	+$72.7K	0.01%	792
2016 Q4	–	Sell	-15,000	Closed	-$64K	–	920
2016 Q3	$64K	Sell	15,000 -4,500	-23%	-$14.6K	0.01%	776
2016 Q2	$47K	Buy	19,500 +6,000	+44%	+$21.7K	0.01%	733
2016 Q1	$63K	Sell	13,500 -3,033	-18%	-$11.7K	0.01%	687
2015 Q4	$65K	Buy	16,533 +3,500	+27%	+$16.1K	0.01%	672
2015 Q3	$50K	Buy	13,033 +2,000	+18%	+$9.19K	0.01%	665
2015 Q2	$51K	Buy	+11,033	New	+$106K	0.01%	688

Other funds holding AST

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NFC

Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Wedbush Securities's AST Position: Q1 2018 in Review

Wedbush Securities sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q1 2018, closing a stake of 11,000 shares — an estimated $25K sold.

Wedbush Securities first reported a position in AST in Q2 2015 and held it in 8 quarters. The position peaked at $65K in Q4 2015. 72 funds tracked by Wall St. Rank hold AST as of Q1 2018.

Wedbush Securities reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q1 2018 after selling out during the quarter.
Wedbush Securities sold 11,000 Asterias Biotherapeutics Inc. Series A shares in Q1 2018, an estimated $25K.
Wedbush Securities first reported a position in Asterias Biotherapeutics Inc. Series A in Q2 2015 and held it in 8 quarters.
Wedbush Securities's Asterias Biotherapeutics Inc. Series A position peaked at $65K in Q4 2015.
72 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q1 2018.

Based on Wedbush Securities's 13F filing for Q1 2018, filed 1 May 2018.